Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Device Pre-Market Submissions Will Soon Require Pediatric Information

This article was originally published in The Gray Sheet

Executive Summary

Beginning this August, pre-market approval applications will be required to include additional data on pediatric patients who suffer from diseases or conditions treated by the sponsor's device, according to a March 31 FDA rule

You may also be interested in...



FDA Proposal Requires Firms To Submit Public Data On Pediatric Populations

The Feb. 19 proposed rule implements requirements from the Pediatric Medical Device Safety and Improvement Act – passed as part of the 2007 FDA Amendments Act. The rulemaking was held up by concerns expressed by industry, which appear to have been addressed by the agency.

FDA Withdraws Pediatric Data-Submission Rule, But Aims To Regroup Shortly

FDA has 1withdrawn a new regulation that would have required companies to submit additional pediatric patient data as part of pre-market submissions beginning next month, but says it hopes to finalize a possibly revised version soon

FDA Withdraws Pediatric Data-Submission Rule, But Aims To Regroup Shortly

FDA has 1withdrawn a new regulation that would have required companies to submit additional pediatric patient data as part of pre-market submissions beginning next month, but says it hopes to finalize a possibly revised version soon

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028692

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel